ABBV SEC Filings: 8-K, 10-Q, S-3 & 424B – AbbVie

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 3, 2026

11-K

Form 11-K - Annual report of employee stock purchase, savings and similar plans

Jun 24, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 20, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2025

News

TYPE

HEADLINE

FILED AT

8-K

AbbVie Inc. Announces Resignation of Director Jennifer L. Davis

Nov 2, 2026

8-K

AbbVie Reports Third-Quarter 2026 Financial Results and Raises Full-Year Guidance

Oct 30, 2026

8-K

AbbVie Expands Board of Directors and Appoints Dr. John M. Carethers

Oct 15, 2026

8-K

AbbVie Updates 2026 Guidance to Include Third-Quarter Acquired IPR&D and Milestones Expense

Oct 5, 2026

8-K

AbbVie Completes Acquisition of Apogee Therapeutics

Sep 3, 2026

8-K

AbbVie Completes $10.75 Billion Senior Notes Offering to Fund Apogee Therapeutics Acquisition

Aug 18, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Aug 6, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Morgan Stanley; BofA Securities; J.P. Morgan; Société Générale

Aug 4, 2026

424B5

FIXED PRICE OFFERING - SENIOR NOTES | Offering amount: $8,000,000,000 | Bank: J.P. Morgan

Feb 26, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: J.P. Morgan, BofA Securities, Morgan Stanley, Wells Fargo Securities

Feb 24, 2026

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Feb 20, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Feb 18, 2025

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 23, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 23, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 9, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 24, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 24, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 10, 2025

Ownerships

TYPE

HEADLINE

FILED AT

144

NEWForm 144 - Report of proposed sale of securities

Nov 9, 2026

Carethers John (Reporting)

Oct 23, 2026

Quaggin Susan E (Reporting)

Oct 2, 2026

RAPP EDWARD J (Reporting)

Oct 2, 2026

Donoghoe Nicholas (Reporting)

Aug 18, 2026

144

Form 144 - Report of proposed sale of securities

Aug 14, 2026

Other

TYPE

HEADLINE

FILED AT

Form SD - Specialized disclosure report

Jun 1, 2026

Form SD - Specialized disclosure report

May 30, 2025

Form SD - Specialized disclosure report

May 31, 2024

Form SD - Specialized disclosure report

May 31, 2023

LETTER

Form UPLOAD - SEC-generated letter

Oct 20, 2022

CORRESP

Form CORRESP - Correspondence

Oct 4, 2022

AbbVie Inc. ABBV · SEC Filings